<DOC>
	<DOCNO>NCT00004897</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug combine chemotherapy interferon alfa , surgery , and/or radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy interferon alfa follow surgery and/or radiation therapy treat patient stage I , stage II , stage III esophageal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Interferon Alfa Followed Surgery and/or Radiation Therapy Treating Patients With Stage I , Stage II , Stage III Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , performance status patient stage I-III esophageal cancer treatment cisplatin , fluorouracil , interferon alfa , leucovorin calcium . II . Determine toxicity regimen patient . III . Determine relapse survival rate patient population treat regimen . IV . Determine response rate , duration response , performance status , relapse survival rate inoperable candidate patient population treat regimen follow radiotherapy . V. Determine toxicity regimen follow radiotherapy patient . VI . Evaluate recurrence follow treatment regimen patient population . VII . Compare roentgenographic ultrasound response histopathologic response regimen patient population . VIII . Evaluate effect regimen relation ability achieve negative surgical margin evaluate extent multifocality , nodal disease , tumor size , tumor grade . IX . Determine incidence perioperative complication follow regimen , include surgical well operative time , blood loss , perioperative transfusion , length hospital stay . OUTLINE : Patients receive leucovorin calcium IV continuously day 1-5.5 , interferon alfa subcutaneously daily day 1-6 , cisplatin IV 6 hour day 1 , fluorouracil IV continuously day 1-5 . Treatment continue every 21 day 3 course absence unacceptable toxicity . Approximately 4 week chemotherapy , esophagectomy perform patient without evidence locally advance unresectable esophageal cancer distant metastasis . Patients determine residual disease follow esophagectomy consider radiotherapy . Patients undergo esophagectomy receive chemoradiotherapy 21-28 day completion initial chemotherapy . Patients receive oral hydroxyurea every 12 hour day 0-5 fluorouracil IV continuously day 1-5 . Patients undergo radiotherapy esophagus daily day 1-5 . Treatment continue every 14 day 7 course absence unacceptable toxicity . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : Approximately 15-45 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven stage IIII squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction Unidimensionally measurable disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 270 day Hematopoietic : WBC great 3,000/mm3 Granulocyte count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin , alkaline phosphatase , SGOT great 2 time upper limit normal ( ULN ) Renal : Creatinine le 2.0 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : No serious cardiovascular disease would preclude study Other : No prior concurrent malignancy within past 5 year except nonmelanoma skin cancer No serious chronic medical illness would preclude study No acute chronic unresolved infection Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>